Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H26O5 |
Molecular Weight | 298.3746 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4
InChI
InChIKey=SXYIRMFQILZOAM-HVNFFKDJSA-N
InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
Molecular Formula | C16H26O5 |
Molecular Weight | 298.3746 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:40:12 UTC 2023
by
admin
on
Fri Dec 15 15:40:12 UTC 2023
|
Record UNII |
C7D6T3H22J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
P01BF01
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
NDF-RT |
N0000175482
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
FDA ORPHAN DRUG |
245507
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
WHO-ATC |
P01BE02
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1 (ART/LUM)
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/09/702
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
||
|
NCI_THESAURUS |
C271
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C7D6T3H22J
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
ARTEMETHER
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
68911
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
CHEMBL566534
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
C032942
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
665970
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
18343
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | RxNorm | ||
|
Artemether and Lumefantrine
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
SUB05574MIG
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
195280
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
C7D6T3H22J
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
1042780
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
m2075
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | Merck Index | ||
|
C73001
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
DTXSID7040651
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
DB06697
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
7456
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
ARTEMETHER
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | Description: White crystals or a white, crystalline powder. Solubility: Practically insoluble in water; very soluble in dichloromethane R and acetone R; freely soluble in ethyl acetate R and dehydrated ethanol R. Category: Antimalarial drug. Storage: Artemether should be kept in a tightly closed container and protected from light. Labelling: The designation Artemether for parenteral use indicates that the substance complies with the additional requirements and may be used for parenteral administration. Additional information: The parenteral form is normally intended for intramuscular administration. Requirement: Artemether contains not less than 97.0% and not more than the equivalent of 102.0% of C16H26O5 using ?Assay?, method A, andnot less than 98.0% and not more than the equivalent of 102.0% of C16H26O5 using ?Assay?, method B, both calculated with reference to the dried substance. | ||
|
759820
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
UU-173
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
6458
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
100000092762
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
245
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY | |||
|
71963-77-4
Created by
admin on Fri Dec 15 15:40:12 UTC 2023 , Edited by admin on Fri Dec 15 15:40:12 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||